CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS, UNAUDITED - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Income Statement [Abstract]
Revenues	$ 0	$ 0
Costs and expenses
Operating expenses	9,512,000	326,000
Research and development expenses	47,000	47,000
Loss from operations	(9,559,000)	(373,000)
Other income (expense)
Interest and financing expense	(115,000)	(76,000)
Net Loss	$ (9,674,000)	$ (449,000)
Net loss per common share, basic	$ (0.02)	$ (0.00)
Net loss per common share, diluted	$ (0.02)	$ (0.00)
Weighted average common shares outstanding, basic	438,187,647	393,373,111
Weighted average common shares outstanding, diluted	438,187,647	393,373,111